AZN vs BMY vs SNY Stock Comparison

Astrazeneca, Bristol Myers Squibb and Sanofi Prices as of Nov 13, 2026 Peers: Industry group
AZN Astrazeneca Plc
$184.49 +13.8% 1M +4.1% 1Y
Market cap
$285.12B
P/E
25.8x
Revenue (TTM)
$59.37B
Div. yield
–
Pharmaceuticals Healthcare
6 wins
BMY Bristol Myers Squibb Co
$63.43 +7.0% 1M +30.4% 1Y
Market cap
$128.63B
P/E
13.9x
Revenue (TTM)
$50.03B
Div. yield
–
Pharmaceuticals Healthcare
2 wins
SNY Sanofi
$48.37 +21.6% 1M -7.6% 1Y
Market cap
$59.05B
P/E
6.2x
Revenue (TTM)
$55.00B
Div. yield
–
Pharmaceuticals Healthcare
3 wins

Head to Head

11 decided of 12

Astrazeneca leads on 6 of the 12 questions below (Astrazeneca 6, Sanofi 3, Bristol Myers Squibb 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAZNBMYSNYLeader
Larger companyMarket capitalisation $285.12B $128.63B $59.05B AZN
Cheaper on earningsLower P/E, profitable companies only 25.8x 13.9x 6.2x SNY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.4x 9.4x 10.4x BMY
Faster revenue growthRevenue growth, trailing twelve months +7.8% +4.2% -19.6% AZN
More profitableNet margin, trailing twelve months 18.6% 18.5% 17.2% AZN
Better return on capitalReturn on invested capital 23.1% 14.0% — AZN
Less leveragedLower net debt / EBITDA -0.7x 2.1x — AZN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +4.1% +30.4% -7.6% BMY
Better 5-year returnAnnualised price return, 5 years +9.4%/yr +1.3%/yr -1.0%/yr AZN
Less volatileAnnualised volatility, 1 year 28.1% 27.9% 24.1% SNY
Higher overall scoreMean of the five percentile scores vs peers 74/100 66/100 83/100 SNY

Percentile Scorecard

AZNBMYSNY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAZNBMYSNY
Valuation 85 #102 of 660 86 #91 of 660 99 #11 of 660
Growth 57 #268 of 619 48 #323 of 619 55 #280 of 619
Profitability 94 #36 of 595 92 #46 of 595 95 #30 of 595
Financial Health 65 #237 of 683 21 #542 of 683 –
Shareholder Returns 67 #151 of 459 82 #82 of 459 85 #68 of 459
Overall 74 66 83
  • AZN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • BMY ranked among 695 companies in Pharmaceuticals and Biotechnology
  • SNY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAZNBMYSNYSPY
1 month +13.8%+7.0%+21.6% -2.0%
3 months +17.9%-0.6%+10.6% -2.8%
6 months +1.6%+11.3%+13.3% +2.0%
Year to date +0.3%+17.6%-0.2% +10.6%
1 year +4.1%+30.4%-7.6% +12.2%
3 years +43.6%+25.6%+5.8% +68.1%
3 years, per year +12.8%+7.9%+1.9% +18.9%
5 years +56.9%+6.7%-4.7% +61.4%
5 years, per year +9.4%+1.3%-1.0% +10.1%
10 years +229.7%+12.5%+17.9% +248.5%
10 years, per year +12.7%+1.2%+1.7% +13.3%

Risk

MeasureAZNBMYSNYSPY
Volatility, 1Y 28.1%27.9%24.1% 13.6%
Downside volatility, 1Y 26.9%25.9%24.8% 13.9%
Beta vs S&P 500, 1Y 0.190.230.28 1.00
Return / volatility, 1Y 0.151.09-0.31 0.90
Max drawdown, 5Y -27.9%-51.1%-35.2% -25.4%
From 52-week high -11.9%-6.8%-7.6% -3.2%
52-week high $209.48$68.09$52.34 $779.14
52-week low $155.60$45.79$39.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAZNBMYSNY
P/E now vs peer median 25.9xmedian 17.0x 14.0xmedian 17.0x 6.2xmedian 17.0x
P/S now vs peer median 4.8xmedian 8.4x 2.6xmedian 8.4x 1.1xmedian 8.4x
EV/EBITDA now vs peer median 12.8xmedian 14.6x 11.3xmedian 14.6x 8.5xmedian 14.6x
P/FCF now vs peer median 26.9xmedian 19.0x 14.0xmedian 19.0x 4.1xmedian 19.0x
P/B now vs peer median 5.5xmedian 2.0x 5.5xmedian 2.0x —median 2.0x
PEG now vs peer median 1.12median 0.43 3.60median 0.43 24.27median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAZNBMYSNY
Revenue $59.37B $50.03B $55.00B
Gross profit $51.12B $34.64B $63.47B
Operating income $14.78B $11.33B $11.14B
Net income $11.03B $9.24B $7.19B
Free cash flow $10.63B $9.29B $14.54B
R&D $15.30B $10.56B $17.81B
EPS (diluted) $7.06 $4.50 $7.72
Cash & equivalents $7.94B $9.57B $6.77B
Total debt -$5.53B $42.88B –
Shares (diluted) 1.56B 2.05B 1.23B
Enterprise value $258.77B $83.82B $29.25B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAZNBMYSNY
P/E 25.9x 14.0x 6.2x
P/FCF 26.9x 14.0x 4.1x
P/Operating cash flow 21.6x 12.2x 3.2x
P/S 4.8x 2.6x 1.1x
P/B 5.5x 5.5x –
P/Tangible book 20.9x 20.0x –
EV/EBITDA 12.8x 11.3x 8.5x
EV/EBIT 18.3x 14.1x 4.7x
EV/Revenue 4.6x 3.2x 0.9x
EV/FCF 25.5x 17.2x 3.6x
EV/Operating cash flow 20.5x 15.0x 2.8x
PEG (3Y EPS CAGR) 1.12 3.60 24.27

Growth

14 metrics
MetricAZNBMYSNY
Revenue growth (1Y) 7.8% 4.2% -19.6%
Revenue CAGR (3Y) 10.3% 3.6% 6.3%
Gross profit growth (1Y) 6.7% 3.8% 86.6%
Gross profit CAGR (3Y) 12.3% 0.2% 23.2%
Operating income growth (1Y) 15.4% 41.1% 24.9%
Operating income CAGR (3Y) 22.6% 9.5% -3.4%
Net income growth (1Y) 17.3% 52.8% -30.1%
Net income CAGR (3Y) 23.2% 3.6% -9.6%
EPS growth (1Y) 17.5% 52.0% -12.4%
EPS CAGR (3Y) 23.2% 3.9% 0.3%
Operating cash flow growth (1Y) -12.6% -35.9% 45.1%
Operating cash flow CAGR (3Y) – -6.2% 20.9%
Free cash flow growth (1Y) -22.8% -39.3% -10.0%
Free cash flow CAGR (3Y) – -7.4% 11.9%

Profitability

14 metrics
MetricAZNBMYSNY
Gross margin 86.1% 69.2% 115.4%
EBITDA margin 35.7% 28.2% 11.2%
Operating margin 24.9% 22.6% 20.3%
Pretax margin 22.4% 22.6% 22.9%
Net margin 18.6% 18.5% 17.2%
FCF margin 17.9% 18.6% 26.4%
Operating cash flow margin 22.3% 21.3% 33.5%
Return on equity 21.6% 40.4% –
Return on assets 9.4% 10.5% 4.9%
Return on invested capital 23.1% 14.0% –
Return on capital employed 9.9% 16.3% –
Asset turnover 0.5x 0.6x 0.4x
Cash conversion (OCF / net income) 1.2x 1.2x 2.6x
Stock comp / revenue – 1.1% –

Financial Health

11 metrics
MetricAZNBMYSNY
Debt / assets -5.6% 48.3% –
Debt / equity -0.1x 1.8x –
Net debt / EBITDA -0.7x 2.1x –
Debt / FCF -0.6x 4.6x –
Liabilities / assets 56.8% 73.6% –
Equity / assets 43.2% 26.4% –
Interest coverage 16.1x – 11.9x
Current ratio -1.0x 1.6x –
Quick ratio -0.8x 1.2x –
Cash ratio -0.3x 0.7x –
Altman Z-score 4.21 2.66 –

Shareholder Returns

7 metrics
MetricAZNBMYSNY
Dividend yield 1.3% 4.0% 5.0%
Net buyback yield 0.0% – -0.2%
Shareholder yield 1.3% 4.0% 4.8%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAZNBMYSNY
Forward P/E 18.4xFY2026 9.4xFY2026 10.4xFY2026
EPS, next fiscal year $10.00FY2026 $6.74FY2026 $4.67FY2026
EPS growth, next FY +9.2%FY2026 +9.6%FY2026 0.0%FY2026
EPS growth, the year after +5.7% -4.2% +5.8%
Revenue, next fiscal year $58.85BFY2026 $52.37BFY2026 $54.79BFY2026
Revenue growth, next FY +0.2%FY2026 +8.7%FY2026 -0.5%FY2026
Revenue growth, the year after +7.8% -9.3% +14.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAZNBMYSNY
Held by institutions 52.1% 81.8% 15.5%
Institutions holding 1,498 2,526 719
Change in shares held, QoQ +7.8% +3.8% -9.8%
Institutions buying 809 1,187 304
Institutions selling 469 991 294
Buyers to sellers 1.72 1.20 1.03

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AZNBMYSNY
AZN 1.00 0.48 0.48
BMY 0.48 1.00 0.47
SNY 0.48 0.47 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AZN, BMY and SNY?

Astrazeneca (AZN) is the largest by market capitalisation: Astrazeneca (AZN) $285.12B, Bristol Myers Squibb (BMY) $128.63B, Sanofi (SNY) $59.05B.

Which stock is cheaper, AZN, BMY and SNY?

Sanofi (SNY) trades on the lowest price-to-earnings ratio (Astrazeneca (AZN) 25.8x, Bristol Myers Squibb (BMY) 13.9x, Sanofi (SNY) 6.2x). On next year's consensus earnings, Bristol Myers Squibb (BMY) is cheapest (Astrazeneca (AZN) 18.4x, Bristol Myers Squibb (BMY) 9.4x, Sanofi (SNY) 10.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Astrazeneca (AZN) grew revenue fastest over the trailing twelve months: Astrazeneca (AZN) +7.8%, Bristol Myers Squibb (BMY) +4.2%, Sanofi (SNY) -19.6%.

Which company is more profitable?

Astrazeneca (AZN) has the highest net margin (Astrazeneca (AZN) 18.6%, Bristol Myers Squibb (BMY) 18.5%, Sanofi (SNY) 17.2%). On return on invested capital, Astrazeneca (AZN) leads (Astrazeneca (AZN) 23.1%, Bristol Myers Squibb (BMY) 14.0%).

Which stock has performed better?

Over the past year Bristol Myers Squibb (BMY) returned the most: Astrazeneca (AZN) +4.1%, Bristol Myers Squibb (BMY) +30.4%, Sanofi (SNY) -7.6%. Over five years, Astrazeneca (AZN) compounded fastest (Astrazeneca (AZN) +9.4%/yr, Bristol Myers Squibb (BMY) +1.3%/yr, Sanofi (SNY) -1.0%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Sanofi (SNY) has been the steadiest (Astrazeneca (AZN) 28.1%, Bristol Myers Squibb (BMY) 27.9%, Sanofi (SNY) 24.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AZN, BMY and SNY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Astrazeneca (AZN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.